Nasdaq: $29.19 (-0.44) | AIM: £4.04 (-0.34)
About Us

HUTCHMED is  an innovative, commercial-stage biopharmaceutical company committed to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capability. As of 2020, we have an in-house scientific team of over 600 professionals, and a pipeline of 10 clinical stage drug candidates in clinical studies around the world.

We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes prescription drugs and consumer health products, as well as two of our marketed novel oncology products – ELUNATE® (fruquintinib capsules)and SULANDA® (surufatinib capsules) - in China.  We are expanding the geographic scope of our commercial operations to include the U.S. and Europe.

HUTCHMED is listed on the Nasdaq Global Select Market and on the London Stock Exchange’s AIM market (Nasdaq/AIM : HCM).

2000
FOUNDED
600+
SCIENTIFIC TEAM
BASED IN CHINA, US,
EUROPE & AUSTRALIA
420
DEDICATED ONCOLOGY
COMMERCIAL TEAM IN CHINA
10
IN-HOUSE DISCOVERED
CLINICAL STAGE DRUG CANDIDATE
2
APPROVED PRODUCTS
IN CHINA
1
NDA SUBMISSION
INITIATED IN THE U.S.
~40
CLINICAL TRIALS
AROUND THE GLOBE
HCM
NASDAQ &
LONDON AIM